List view / Grid view
25 January 2016 | By Victoria White
The FDA has approved Opdivo (nivolumab) + Yervoy (ipilimumab) for the treatment of patients with BRAF V600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma...
25 January 2016 | By Victoria White
Amgen has announced results from a study of Vectibix and best supportive care in patients with chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC)...
25 January 2016 | By Victoria White
Celgene has announced results from multiple analyses evaluating second-line treatments following Abraxane and gemcitabine (AG) in metastatic pancreatic cancer patients.
22 January 2016 | By Victoria White
GlobalData states that the impressive growth will primarily be driven by the launch of premium-priced therapies, including anti-PD-1 and anti-CTLA-4 immunotherapies and targeted agents...
22 January 2016 | By Victoria White
The EC has approved the Type II variation for Adcetris to include data on the retreatment of adult patients with R/R Hodgkin lymphoma or R/R sALCL who previously responded to Adcetris and who later relapse....
22 January 2016 | By Victoria White
The decision includes an update of the product information of all ambroxol and bromhexine containing products to include the rare risk of hypersensitivity reactions and a Precaution and Warning regarding severe cutaneous adverse reactions...
22 January 2016 | By Victoria White
The FDA has approved the supplemental New Drug Application (sNDA) of Amgen’s Kyprolis (carfilzomib) for injection in combination with dexamethasone or with lenalidomide plus dexamethasone...
22 January 2016 | By Victoria White
NICE recommends that nivolumab is made available on the NHS as a treatment option for patients with advanced (unresectable or metastatic) melanoma...
21 January 2016 | By Victoria White
In the Phase III trials, significantly more patients treated with Viberzi experienced improvements in diarrhoea and abdominal pain, as compared with placebo...
21 January 2016 | By Victoria White
The pulmonary arterial hypertension treatment market will grow from $3.45 billion in 2014 to $4.75 billion by 2024, according to research and consulting firm GlobalData...
21 January 2016 | By Victoria White
Vasopharm has designed a Phase III registration study in Europe of VAS203 in in moderate to severe traumatic brain injury...
21 January 2016 | By Victoria White
More than 80 companies and organisations have signed the Declaration on Combating Antimicrobial Resistance (AMR), an industry-wide call to action...
21 January 2016 | By Sartorius Stedim Biotech
The ideal solution for scaling studies and low volume ultra- and diafiltration operations...
20 January 2016 | By Victoria White
Venetoclax is an investigational small molecule designed to selectively bind and inhibit the BCL-2 protein, which plays an important role in a process called apoptosis...
20 January 2016 | By Victoria White
Gavi has provided US$ 5 million towards the development of Merck’s rVSV∆G-ZEBOV-GP live attenuated Ebola Zaire vaccine, on the understanding that it will be submitted for licensure by the end of 2017...
